C4 Therapeutics Inc (NASDAQ: CCCC) — Company Overview, News & Financial Data
C4 Therapeutics develops novel cancer treatments using its TORPEDO platform to target disease-causing proteins.
C4 Therapeutics Inc
C4 Therapeutics (NASDAQ:CCCC) specializes in developing novel cancer treatments based on its cutting-edge technology platform aimed at degrading disease-causing proteins. By leveraging their proprietary TORPEDO platform, the company focuses on creating targeted therapies that have the potential to bring transformative outcomes in cancer care. Their projects span across various development stages, from discovery to clinical trials, aiming to tackle multiple types of cancer by disrupting the protein degradation pathway. The primary objective of C4 Therapeutics is to advance their pipeline of targeted oncology treatments, thereby offering new hope and options for patients grappling with cancer. Through rigorous research and development efforts, the company aspires to pioneer a new wave of oncology therapeutics that can effectively address unmet medical needs in the cancer treatment landscape.
Snapshot
Operations
Products and/or services of C4 Therapeutics Inc
- Targeted protein degradation platform, using proprietary molecules to harness the body's natural protein disposal system for treating cancer and other diseases.
- CFT7455, a MonoDAC™ inhibitor for the treatment of hematologic malignancies including multiple myeloma, non-Hodgkin lymphomas, and acute myeloid leukemia.
- CFT8634, a BiDAC™ inhibitor designed to degrade BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted solid tumors.
- CFT1946, a BiDAC™ inhibitor targeting BRAF V600 mutations for the treatment of BRAF V600 mutant solid tumors, advancing precision medicine.
- Collaboration with Roche to develop novel degraders against a range of cancer targets, leveraging mutual expertise to enhance the efficacy and safety of cancer treatments.
- Partnership with Biogen focused on applying protein degradation technology to discover and develop novel therapies for neurological diseases, aiming to address unmet medical needs.
C4 Therapeutics Inc executive team
- Andrew J. HirschCEO, President & Director
- Kenneth C. AndersonCo-Founder, Independent Director & Member of Scientific Advisory Board
- Kendra R. AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer
- Leonard M. J. ReynoChief Medical Officer
- Nathanael S. GrayCo-Founder & Member of Scientific Advisory Board
- Courtney SolbergSenior Manager of Investor Relations
- Kelly A. SchickChief People Officer
- Isabel ChiuSenior Vice President of Strategic Alliances & Business Development
- Christopher NasveschukSenior Vice President of Chemistry
- Roy PollockSenior Vice President of Biological Sciences
Key financials
Reported results for C4 Therapeutics Inc, in USD.
- Market cap
- 394.9M
- Revenue (TTM)
- 35M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.9
- Dividend yield
- —
- Profit margin
- -289.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 35.9M | -104.5M | -105M | |
| 35.6M | -119.6M | -105.3M | |
| 20.8M | -139M | -132.5M | |
| 31.1M | -129.5M | -128.2M |